Retatrutide Dosing Guide 2026:
What the Phase 2 Data Shows

Unlike single-target GLP-1 peptides like Semaglutide, Retatrutide activates three receptor pathways simultaneously: GLP-1 (appetite suppression), GIP (insulin sensitivity and fat metabolism), and Glucagon (direct energy expenditure and hepatic lipid clearance). This triple mechanism is what drives its unmatched efficacy — and it is also why its dose-response curve is steeper and more consequential than anything else in this class.

Starting too high amplifies GI side effects dramatically. Starting too low and escalating too fast produces the same outcome. The Phase 2 trial titration protocol was specifically designed to balance efficacy against tolerability — and the data gives us a clear framework to work from.

The glucagon component is dose-proportional — meaning higher doses drive disproportionately greater energy expenditure. This makes correct titration essential: too much glucagon activity without adequate caloric adjustment can accelerate muscle catabolism alongside fat loss.

The dose-response relationship is notably non-linear between 8mg and 12mg — weight loss increases only ~1.4 percentage points while adverse event rates jump significantly. This is why 8mg represents a compelling maintenance dose for many research protocols: near-maximum efficacy with a meaningfully better tolerability profile.

At 12mg, nausea affected 43% of trial participants — almost half. GI side effects were the primary driver of the 18.2% discontinuation rate at this tier. The practical implication: reaching 12mg is only advisable after thorough dose-escalation and confirmed GI tolerance at 8mg.

Based on Phase 2 trial design and observed tolerability data, the appropriate starting dose for a Retatrutide research protocol is 1mg subcutaneously once weekly for the first four weeks. Some protocols begin at 2mg if prior GLP-1 agonist experience is established, but 1mg provides the cleanest tolerability baseline for peptide-naive subjects.

If 1mg is well-tolerated through week 4 — defined as no persistent nausea beyond 48 hours post-injection, no vomiting, and stable energy levels — escalation to 2mg is appropriate.

Pausing escalation: If any dose step produces persistent nausea beyond 72 hours, vomiting, significant diarrhea, or appetite suppression severe enough to impair adequate protein intake, hold at the current dose for an additional 4 weeks before attempting escalation. Do not push through GI intolerance — it is the primary cause of discontinuation in the trial data.

De-escalation: If adverse events are significant at any tier, stepping back to the prior dose for 2–4 weeks and re-escalating more slowly is the appropriate response. The titration schedule is a framework, not a fixed timeline.

Retatrutide's subcutaneous half-life is approximately 6 days, making it near-perfectly suited to once-weekly administration. This pharmacokinetic profile was a primary design criterion — Eli Lilly engineered the molecule's half-life to allow weekly subcutaneous injection with stable plasma concentrations between doses.

The 6-day half-life means that weekly dosing is essentially mandated by the pharmacokinetics. There is no clinical or mechanistic rationale for bi-weekly Retatrutide administration. Any protocol deviating from weekly injection is operating outside the evidence base entirely.

The Phase 2 trial used fixed absolute doses (1mg, 2mg, 4mg, 8mg, 12mg) rather than weight-adjusted dosing. This means the trial data does not support a straightforward mg/kg calculation. However, body weight context is still relevant to protocol design in several ways.

The practical guidance: titrate to the highest dose that maintains tolerable side effects, independent of body weight. The dose tiers are fixed; the variable is how quickly and how far you escalate based on individual GI and metabolic response.

Retatrutide for research is typically supplied as a lyophilized (freeze-dried) powder in sealed vials. Proper reconstitution and storage directly impacts peptide stability and therefore the reliability of dosing accuracy.

A 15mg vial reconstituted at 10mg/mL provides 1.5 mL of solution. At a 1mg weekly dose, that is 15 weeks of supply per vial. At 8mg weekly, a single 15mg vial covers approximately 1.9 doses — meaning a 30mg vial is the practical minimum for a single month at high-dose maintenance.